Connect Biopharma Holdings (CNTB) Net Cash Flow (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported Net Cash Flow for 3 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.

• Quarterly Net Cash Flow rose 124.89% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.1 million (up 96.85% YoY) and the FY2025 annual result came in at -$40.3 million, down 50.15% from the prior year.
• Net Cash Flow rose to $7.6 million in Q1 2026 per CNTB's latest filing, from $449000.0 in the prior quarter.
• Over the last five years, Net Cash Flow for CNTB reached as high as $8.7 million in Q1 2024 and fell as low as -$30.6 million in Q1 2025.
• A 3-year average of -$6.6 million and a median of -$4.4 million in 2024 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2025 — Net Cash Flow tumbled 453.37% — and 2026, when it soared 124.89%.
• Year by year, Net Cash Flow stood at -$18.0 million in 2024, then jumped by 102.5% to $449000.0 in 2025, then jumped by 1596.44% to $7.6 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $7.6 million, $449000.0, and -$2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.